NO20022591D0 - Finmalt form av (S)-2-etoksy-3-[4-(2-{4- metansulfonyloksyfenyl}etoksy)fenyl]propansyre - Google Patents

Finmalt form av (S)-2-etoksy-3-[4-(2-{4- metansulfonyloksyfenyl}etoksy)fenyl]propansyre

Info

Publication number
NO20022591D0
NO20022591D0 NO20022591A NO20022591A NO20022591D0 NO 20022591 D0 NO20022591 D0 NO 20022591D0 NO 20022591 A NO20022591 A NO 20022591A NO 20022591 A NO20022591 A NO 20022591A NO 20022591 D0 NO20022591 D0 NO 20022591D0
Authority
NO
Norway
Prior art keywords
ethoxy
methanesulfonyloxyphenyl
phenyl
propanoic acid
finely form
Prior art date
Application number
NO20022591A
Other languages
English (en)
Norwegian (no)
Other versions
NO20022591L (no
Inventor
Agneta Hallgren
Kristina Roos
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20022591D0 publication Critical patent/NO20022591D0/no
Publication of NO20022591L publication Critical patent/NO20022591L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20022591A 1999-12-03 2002-05-31 Finmalt form av (S)-2-etoksy-3-[4-(2-{4- metansulfonyloksyfenyl}etoksy)fenyl]propansyre NO20022591L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904413A SE9904413D0 (sv) 1999-12-03 1999-12-03 Comminuted form
PCT/SE2000/002381 WO2001040169A1 (en) 1999-12-03 2000-11-29 Comminuted form of (s)-2-ethoxy -3-[4-(2- {4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid

Publications (2)

Publication Number Publication Date
NO20022591D0 true NO20022591D0 (no) 2002-05-31
NO20022591L NO20022591L (no) 2002-05-31

Family

ID=20417978

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022591A NO20022591L (no) 1999-12-03 2002-05-31 Finmalt form av (S)-2-etoksy-3-[4-(2-{4- metansulfonyloksyfenyl}etoksy)fenyl]propansyre

Country Status (32)

Country Link
EP (1) EP1237854B1 (is)
JP (1) JP2003515580A (is)
KR (1) KR20020067538A (is)
CN (1) CN1216859C (is)
AR (1) AR029456A1 (is)
AT (1) ATE251131T1 (is)
AU (1) AU766036B2 (is)
BR (1) BR0016135A (is)
CA (1) CA2392029A1 (is)
CO (1) CO5271736A1 (is)
CZ (1) CZ20021839A3 (is)
DE (1) DE60005710T2 (is)
DK (1) DK1237854T3 (is)
EE (1) EE200200284A (is)
ES (1) ES2208444T3 (is)
HK (1) HK1049324B (is)
HU (1) HUP0203692A3 (is)
IL (1) IL149516A0 (is)
IS (1) IS6399A (is)
MX (1) MXPA02005165A (is)
MY (1) MY125099A (is)
NO (1) NO20022591L (is)
NZ (1) NZ518926A (is)
PL (1) PL355372A1 (is)
PT (1) PT1237854E (is)
RU (1) RU2248966C2 (is)
SE (1) SE9904413D0 (is)
SK (1) SK7662002A3 (is)
TR (1) TR200400003T4 (is)
UA (1) UA73959C2 (is)
WO (1) WO2001040169A1 (is)
ZA (1) ZA200203797B (is)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL193086B1 (pl) 1997-10-27 2007-01-31 Reddys Lab Ltd Dr Nowe związki tricykliczne i związki pośrednie, sposób ich wytwarzania, zawierające je kompozycje farmaceutyczne oraz ich zastosowanie
HUP0101110A3 (en) 1997-10-27 2002-06-28 Reddys Lab Ltd Dr Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
CN1280574A (zh) 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
US6531596B1 (en) 1998-10-29 2003-03-11 Dr. Reddy's Laboratories Ltd. Process for the preparation of new antidiabetic agents
UA60386C2 (uk) 1998-10-29 2003-10-15 Reddys Laboratories Ltd Спосіб одержання похідних 3-[4-[2-(феноксазин-10-іл)метокси]феніл]пропіонової кислоти (варіанти) та проміжні сполуки для їх отримання
US6897199B2 (en) 2001-02-05 2005-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
BRPI0416639A (pt) 2003-11-19 2007-01-16 Metabasis Therapeutics Inc tiromiméticos contendo fósforo
EP1586573B1 (en) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, processes for their preparation and their use as pharmaceuticals
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
AU2007293885A1 (en) 2006-09-07 2008-03-13 Takeda Gmbh Combination treatment for diabetes mellitus
CN101790512A (zh) 2007-03-08 2010-07-28 阿尔比里奥公司 2-取代-3-苯基丙酸衍生物及其在炎性肠病治疗中的用途
WO2008149345A2 (en) 2007-06-04 2008-12-11 Ben-Gurion University Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
US10111880B2 (en) 2013-11-05 2018-10-30 Ben-Gurion University Of The Negev Research And Development Authority Compounds for the treatment of diabetes and disease complications arising from same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9704873D0 (sv) * 1997-12-23 1997-12-23 Astra Ab Sampling apparatus
MA26634A1 (fr) * 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues

Also Published As

Publication number Publication date
PT1237854E (pt) 2004-02-27
PL355372A1 (en) 2004-04-19
ATE251131T1 (de) 2003-10-15
UA73959C2 (en) 2005-10-17
SE9904413D0 (sv) 1999-12-03
CO5271736A1 (es) 2003-04-30
RU2248966C2 (ru) 2005-03-27
KR20020067538A (ko) 2002-08-22
ZA200203797B (en) 2003-08-13
TR200400003T4 (tr) 2004-02-23
DE60005710D1 (en) 2003-11-06
RU2002113169A (ru) 2004-01-20
CZ20021839A3 (cs) 2002-08-14
HK1049324B (zh) 2004-04-30
EP1237854A1 (en) 2002-09-11
WO2001040169A1 (en) 2001-06-07
AU2034801A (en) 2001-06-12
CN1402704A (zh) 2003-03-12
EP1237854B1 (en) 2003-10-01
MXPA02005165A (es) 2003-09-25
ES2208444T3 (es) 2004-06-16
DK1237854T3 (da) 2004-01-12
CN1216859C (zh) 2005-08-31
JP2003515580A (ja) 2003-05-07
AU766036B2 (en) 2003-10-09
EE200200284A (et) 2003-08-15
IL149516A0 (en) 2002-11-10
NO20022591L (no) 2002-05-31
DE60005710T2 (de) 2004-08-05
HK1049324A1 (en) 2003-05-09
IS6399A (is) 2002-05-28
HUP0203692A3 (en) 2005-05-30
SK7662002A3 (en) 2002-10-08
NZ518926A (en) 2003-11-28
BR0016135A (pt) 2002-08-20
CA2392029A1 (en) 2001-06-07
HUP0203692A2 (hu) 2003-03-28
AR029456A1 (es) 2003-07-02
MY125099A (en) 2006-07-31

Similar Documents

Publication Publication Date Title
NO20022591D0 (no) Finmalt form av (S)-2-etoksy-3-[4-(2-{4- metansulfonyloksyfenyl}etoksy)fenyl]propansyre
EE200200278A (et) (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhappe kristalne vorm
LU92025I2 (fr) Méthanesulfonate d'éthylester d'acide 3-¬(2-{¬4-(hexyloxy-carbonylamino-imino-méthyl)-phénylamino-méthyl}-1-méthyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino-propionique
AU3957800A (en) Crystalline r- guanidines, arginine or (l) -arginine (2(s)) -2- ethoxy -3-(4- (2-(10(h) -phenoxazin -10-yl)ethoxy}phenyl)propanoate
DE69927969D1 (de) Kontrollierte freisetzung von liponsäure
EE200000720A (et) Uus 3-arüül-2-hüdroksüpropaanhappe derivaat (I)
ID24626A (id) Turunan-turunan asam hidroksamat sebagai penghambat metaloprotease matriks (mmp)
DK1232152T3 (da) Forbedret fremgangsmåde til fremstilling af nitrogensubstituerede aminotetraliner
ATE338027T1 (de) Herstellung von iminodiessigsäure-derivaten aus monoethanolamin-substraten
EE200300140A (et) PPAR-alfat aktiveerivate omadustega propaanhappe derivaadid
DE69906849D1 (de) Verfahren zur Herstellung von optisch aktiven Phenylpropionsäure-Derivat
AU2003282178A1 (en) Novel method for the industrial synthesis of the methyl diester of 5-amino-3-carboxymethyl-4-cyano-2-thiophenecarboxylic acid and application of divalent salts of ranelic acid and the hydrates thereof in said synthesis
AU2001267416A1 (en) N-sulfonyl hydroxamic acid derivatives as inhibitors of cd 23
AU2034701A (en) Comminuted form of 3-(4-(2-(4-tert-butoxycarbonylaminophenyl)ethoxy)phenyl)-(s) 2-ethoxy propanoic
ID24964A (id) Bentuk-bentuk baru psendopolimorf dari asam dihidroklorida 2-[2-[4-[bis (4-fluorofenil) metil]-1-piperazinil) etoksi asetat
NO20043105L (no) Fremgangsmate for fremstilling av 2-(substituert fenyl)-2-hydroksy-etyl-karbamater
NO20035235D0 (no) Farmasöytisk kombinasjon omfattende enten (S) -2-etoksy-3- (4- (2- (4-metansulfonyloksyfenyl) etoksy) fenyl) propansyre eller 3- (4- (2- (4-tert-butoksykarbonylaminofenyl) etoksy) fenyl)
DE60010725T2 (de) Herstellung von arylcarbonsäureestern
IS7056A (is) Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3 [4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxý própansýru og insúlín
DE50012694D1 (de) Verwendung von fettsäurealkanolaminestern
SI1237854T1 (en) Comminuted form of (s)-2-ethoxy -3- 4-(2- 4-methanesulfonyloxyphenyl ethoxy) phenyl) propanoic acid
IS7058A (is) Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3-[4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxýprópansýru og bígúaníðlyf
DE59904718D1 (de) Verfahren zur Herstellung von Amidosäurephenylestern
DE69902917T2 (de) Verfahren zur Herstellung von 3-(Hydroxyphenyl-Phosphinyl)-Propansäure
NO994261L (no) Fremgangsmåte for fremstilling av trovafloxacinsyresalter